690 High safety and efficacy of CRISPR-Based non-viral PD1 locus specific Integrated Anti-CD19 CAR-T cells (BRL-201) in treating relapsed or refractory non-Hodgkin’s lymphoma: first-in-human phase I study

• Wei Li,
• Guoqing Wei,
• He Huang,
• Mingyao Liu,
• Mingming Zhang,
• Yongxian Hu,
• Wenjun Wu,
• Biao Zheng,
• Jiqin Zhang,
• Jiazhen Cui,
• Bing Du

Affiliations

Wei Li

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, University Teknologi MARA, Beijing, China

Guoqing Wei

Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

He Huang

2 Key Lab of Dermatology, Ministry of Education (Anhui Medical University), Hefei, Anhui, People`s Republic of China

Mingyao Liu

1 Latner Thoracic Surgical Laboratory, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada

Mingming Zhang

3Zhejiang Province Engineering Laboratory for Stem Cell andImmunity Therapy, Hangzhou, Zhejiang, China

Yongxian Hu

Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Wenjun Wu

Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Biao Zheng

1BRL Medicine Inc., Shanghai, China

Jiqin Zhang

1BRL Medicine Inc., Shanghai, China

Jiazhen Cui

2The First AffiliatedHospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Bing Du

1BRL Medicine Inc., Shanghai, China